Huntingtons Ingalls (NYSE:HII) reported Q4 CY2025 revenue of $3.48 billion, up 15.7% year-on-year, and non-GAAP profit of $4.04 per share, 5% above consensus, on February 6, 2026. The strong top line followed higher shipbuilding throughput, supported by expanded outsourcing and workforce investments, but margin progression remains constrained by cost pressures and schedule complexities.

CEO Chris Kastner highlighted broad-based productivity gains across major programs. Management guidance anticipates a 15% increase in throughput in 2026 and a 30% expansion in outsourcing, with continued capital spending on new submarine and surface ship programs. Risks include contract timing, evolving program mix, and inflation.

The company trades at $366.75, down from $413.14, as margin sustainability concerns tempered the positive earnings momentum. Analysts will closely monitor new contract awards, progress toward throughput and outsourcing targets, and signs of margin stabilization in the coming quarters.

Griffon Corporation (NYSE:GFF) reported Q4 CY2025 revenue of $649.1 million, up 2.6% year on year, and non-GAAP profit of $1.45 per share, 8.9% above consensus. The full-year revenue guidance of $1.8 billion is 28.9% below analyst estimates, reflecting a strategic portfolio shift.

Management attributed the quarter’s strength to strong pricing and mix in building products, improved profitability in the Consumer and Professional Products segment, and solid free cash flow from gains in Australia and Canada. CEO Ronald Kramer emphasized operational discipline and a focus on the premium repair/remodel market.

Looking ahead, the company is forming a joint venture for AMES North America and considering divestitures of non-core assets to streamline its portfolio. The guidance reflects ongoing residential demand and material cost uncertainties, balanced by confidence in long-term benefits from the realignment and efficiencies.

Key watchpoints include the joint venture’s progress, disposal of AMES Australia and U.K. operations, and the integration of Hunter Fans. GFF closed at $89.60, up from $84.73 pre-earnings.

Bristol Myers Squibb (NYSE:BMY) reported Q4 CY2025 revenue of $12.5B, up 1.4% YoY, and non-GAAP profit of $1.26/share, 4.6% above consensus. The company’s full-year revenue guidance of $46.75B is 5.7% above estimates. Growth products—Opdualag, Breyanzi, Camzyos, and Reblozyl—each surpassed $1B in annual sales, with Reblozyl crossing $2B. Management credited disciplined cost savings and early-stage pipeline take-up for offsetting declines in legacy brands amid generic competition and patent expirations, including Eliquis.

Looking ahead, pivotal clinical data readouts and label extensions are scheduled through late CY2026, with six new pipeline updates expected. CFO David Elkins said the cost-savings program provides flexibility to reinvest in launches and R&D while navigating pricing shifts and exclusivity loss. Analysts will closely watch pivotal results, execution of cost discipline and reinvestment, and the impact of generics on legacy products.

Q4 CY2025 revenue at BILL (NYSE:BILL) rose 14.4% year-on-year to $414.7 million, beating expectations. Non-GAAP profit of $0.64 per share was 14.2% above consensus, and 2026 guidance at the midpoint of $402.5 million is 1.8% above analyst estimates.

Drivers included stronger SMB adoption, rebounding construction activity, and growth in transaction volumes. New agentic AI features and expanded embedded finance partnerships drove higher engagement and pricing, supported by deliberate rewards and pricing optimization.

Looking ahead, management expects continued momentum from AI automation, deeper integration with accounting firms, and expansion into larger customers to lift revenue per user and margins. BILL closed at $39.55, up from $35.68 pre-earnings.

AGCO (NYSE:AGCO) reported Q4 CY2025 revenue of $2.92 billion, 1.1% higher than the prior year, and full-year revenue guidance of $10.55 billion at the midpoint, 5% above estimates. GAAP profit of $1.29 per share was 25.9% below consensus. Management credits disciplined inventory and targeted cost actions for outperforming sales, but softer production volumes and competitive discounting, especially in North America, weighed on margins.

CEO Eric Hansotia highlighted progress in the PTX precision ag business and dealer network expansion. CFO Damon Audia said ongoing restructuring and cost initiatives are expected to deliver further benefits, while pricing actions aim to offset inflation and tariffs with caution on margin dilution.

AGCO closed at $124.32, up from $121.68 before the earnings. The company is investing in engineering to support new product launches and accelerating cost reductions, with attention on inventory management, automation-driven efficiency, and demand recovery in key markets.

[Para 1: The Lead]

Three mid-cap stocks—Chewy (CHWY), Charles River Laboratories (CRL), and Franklin Resources (BEN)—are被评为 underperforming choices due to high valuations and crowded, competitive environments. Each trades at 13.8x, 19.2x, and 10.6x forward EV/EBITDA or P/E ratios, respectively, suggesting limited near-term growth potential.

[Para 2: Supporting Details]

Chewy (NYSE:CHWY) is an online pet retailer; CRL (NYSE:CRL) provides biopharma R&D and manufacturing support; BEN (NYSE:BEN) is a global investment management firm. Analysts and research reports indicate these stocks present higher risk for investors seeking mid-cap growth, with better opportunities available in the Top 9 Market-Beating Stocks list as of June 30, 2025.

[The Lead]

NASDAQ:MTCH, Electronic Arts (EA), and Remitly (RELY) dominate this week’s focus. While the broader internet sector has declined 17.8% over six months versus the S&P 500’s 8.4% gain, three stocks stand out with potential for outperformance: EA, RELY, and a cautious view on MTCH.

[Body]

Electronic Arts (NASDAQ:EA) trades at $197.99/share, implying a 16.1x forward EV/EBITDA. Remitly (NASDAQ:RELY) is at $12.81/share, or 8.5x forward EV/EBITDA. Match (NASDAQ:MTCH) is at $30.80/share with an 8.2x forward EV/EBITDA, but its valuation exceeds our quality threshold.

MTCH, EA, and RELY each offer distinct growth narratives in online gaming, global payments, and dating platforms. Investors should consider initiating or maintaining positions in the latter two while treating MTCH with caution due to its high multiple and recent underperformance.]

Consumer stocks are climbing 7.2% over the past six months, outpacing the S&P 500, as digitization drives same-store sales growth. However, sector concentration is high—just 4 stocks account for half the index's gains—demanding careful selection.

Urban Outfitters (NASDAQ:URBN) is our top pick at 13.2x forward P/E, trading at $71.16. In contrast, Designer Brands (NYSE:DBI) at $6.74 implies 22.7x forward P/E and is rated a caution, and Petco (NASDAQ:WOOF) at $2.49 implies 12.6x forward P/E and is not recommended. Our research highlights high-quality names with a 244% total return over five years through June 30, 2025, including Nvidia and Comfort Systems.

Industry leaders reacted sharply to the Democratic Party’s Feb 4, 2026, post mocking the crypto market, as Bitcoin plunged 8.1% in the past 24 hours to $65,729, a 33.1% year-over-year loss. The post drew accusations of partisan insensitivity amid $2.6B in 24-hour liquidations, including $1.35B from Bitcoin longs.

Para 2: Coinglass data showed Ethereum facing $443M in long-position liquidations. Executives and advisors cautioned such messaging risks alienating pro-crypto voters ahead of midterms, as partisan tensions over crypto policy intensified following similar tweets from California’s press office and ongoing probes of a $500 million UAE investment in World Liberty Financial.

Encompass Health (EHC) reported fourth-quarter net income of $197.4 million, up 13.2% from $174.8 million in the same period of 2025, surpassing the average analyst estimate of $179.5 million. The company attributed the improvement to higher outpatient and inpatient revenue, as well as favorable insurance reimbursements. For the quarter ended January 3, 2026, EPS was $1.42, exceeding the $1.39 median estimate. Revenue for Q4 rose 4.1% to $3.76 billion.

Software stocks are enduring the most severe sell-off in 25 years, with Wedbush analyst Dan Ives warning that firms such as Salesforce, ServiceNow and Microsoft are facing harsh valuation repricing perceived as ill-prepared for the AI era.

“I can tell you this is the most structural selloff in the software sector in 25 years,” Ives said in a recent interview. “Investors appear to believe software is no longer central to the AI era.”

He cautioned that some companies risk losing about 5% of their customers due to current valuations. While acknowledging AI is reshaping the industry, Ives said the fear of obsolescence is exaggerated, citing Palantir’s success as evidence.

At the Cisco AI Summit, NVIDIA CEO黄仁勋 (Huang Renxun) disputed the notion, stating AI depends on software, not replaces it.

Oracle (ORCL-US) closed lower on Thursday, marking an eighth consecutive trading-day decline as the company faces pressure from a weakening software sector and investor concerns about AI spending. The extended sell-off reflects fears that new AI tools may displace traditional enterprise software, hitting Oracle’s core database business.

Oracle is attempting a shift to an AI cloud model akin to Microsoft (MSFT-US), Amazon (AMZN-US), and Alphabet (GOOGL-US), but rising debt and its close ties to OpenAI have kept sentiment cautious. The eight-day decline was the steepest since May 2002, with the stock down 25.2% from its recent high.

Negative momentum continued in the software sector, with the iShares Expanded Technology Software ETF (IGV-US) falling 19.4% in the same period, the longest eight-day decline since May 2021, and the worst eight-day performance since March 2020.

Since its record high after announcing a $300B cloud partnership with OpenAI in September 2025, Oracle has declined about 60%. The company plans up to $500B in financing through debt and equity in 2026 to meet major client contracts and maintain investment-grade credit ratings. A $250B bond issuance on Monday followed a $180B offering in September.

Credit spreads briefly narrowed to about 30 bps after the issuance but widened slightly afterward. According to The Financial Times, banks are seeking to sell $560B in loans tied to Oracle’s data centers, with insurance companies and private credit funds likely buyers.

Bitcoin plunged to nearly $60,000 on February 6, 2026, a 30% drop in seven days, prompting traders to question whether the selloff was driven by macro factors, a balance-sheet unwind, or a failed recovery in gold and silver. Analysis suggests the decline may be linked to unusually high BlackRock’s IBIT ETF volume of $10.7B and $900M in options premium, consistent with options-driven liquidation rather than a typical leverage unwind.

Speculation also shifts toward security risks, with Charles Edwards of Capriole stating falling prices may finally incentivize meaningful action on quantum-resistant cryptography. The selloff has introduced sharp intraday volatility, thinning liquidity and driving altcoins lower as sentiment drops to levels reminiscent of the FTX crash. Prices are testing levels last seen in late 2024, with traders awaiting reset in institutional and retail flows before considering rebounds.

The U.S. Department of Health and Human Services launched TrumpRx.gov on February 5, 2026, enabling users to purchase prescription drugs directly at prices as low as 10% of list. The move follows a fourfold regulatory package aimed at curbing pricing distortions in the global pharmaceutical sector.

Key provisions require manufacturers to offer the same lowest prices to Medicare and commercial insurers as to domestic purchasers, and to ensure new drugs are not priced higher abroad than in the U.S. The initiative has drawn support from AstraZeneca, Eli Lilly, Novartis, NovoNordisk, and GlaxoSmithKline, covering 40 high-cost medications.

CMS Administrator Dr. Mehmet Oz said the free, price-comparison tool is expected to save about £100 million in GLP-1 drugs this year, with weight-loss medications among the steepest declines. The policy has sent制药 shares in Japan lower, including Takeda and Sony Biosciences, as reaction spreads globally.

The administration argues the rules will preserve U.S. leadership in biopharma and shield consumers from escalating healthcare costs, while offering manufacturers tariff exemptions in exchange. Implementation faces uncertainty, with manufacturers warning of reduced R&D incentives and consumers likely to favor insurance-covered options.

Auto brands and their ecosystem partners are expanding global reach. Seres (NYSE: SRES) announced a strategic partnership with Performance Plus Motors, a unit of Abu Dhabi Motors, to enter the Middle East. The UAE-based dealer will handle sales, delivery, and after-sales service for Aito’s luxury intelligent electric vehicles. The agreement, effective February 6, 2026, does not specify a launch timeline.

AI is not a bubble, according to Simon Lin, chairman of Wistron (TW: 4988), who forecasts 2026 AI-related orders to grow more than 2025. Wistron's order situation is strong through 2027, with significant year-on-year growth expected in 2026. The firm's new U.S. manufacturing facilities for Nvidia will begin operations in the first half of 2026, with volume production starting in Q1 2026. These facilities support Nvidia's plan to build up to $500 billion in AI server manufacturing over the next four years, including supercomputer manufacturing plants in Texas co-located with Foxconn and Wistron.

Apple has indefinitely scaled back its "Mulberry" AI virtual health coach, originally scheduled for release with iOS 27 on September 09, 2026. The internal reorganization aims to fragment and later integrate its core capabilities into the Health app, responding to intensified competition from Oura Health, Whoop, Samsung, Strava, and OpenAI's ChatGPT Health.

With leadership transition from Jeff Williams to Eddy Cue, Apple is accelerating toward active health management. A new AI chatbot leveraging its World Knowledge Answers is being prioritized, and a gait-risk analysis camera feature is continuing development.

Apple Fitness+ is also under review for potential reconfiguration. The company issued no comment on the latest direction.

BYD Co. (002594.HK) is experiencing a sharp selloff as cooling domestic demand and surging raw material costs drive a reset in profit outlooks for China’s electric-vehicle sector. Hong Kong-listed shares have lost more than $60 billion in market value this year, with BYD’s domestic January deliveries down 50% to 109,569 units.

Sales weakness and cost inflation—lithium, copper, and memory chips up over 100%—are pressuring margins, with some mass-market EVs facing an additional $1,000 per unit in costs. Most local automakers expect first-quarter volumes to drop 30–40% from the December quarter.

Bearish positioning in the Hang Seng Tech Index has diverged from the broader Hang Seng, and Nio (0986.HK) posted its first quarterly profit in Hong Kong on Friday. BYD trades at about 16x forward earnings, below its 3-year average of 18x. Analysts caution on earnings downgrades and margin pressure, keeping most investors on the sidelines for now.

Intel (INTC-US) and Advanced Micro Devices (AMD-US) report escalating CPU supply constraints as AI-driven demand outpaces production, pushing delivery cycles to as long as six months for high-end server processors and extending into 2026. China, the world’s largest server market (accounting for over 25% of global units in 2024), faces the most immediate impact, with Intel and AMD implementing allocation-based deliveries and reporting 8–10 week lead times for AMD products.

Inventory is at a historic low, with Intel forecasting Q1 stockouts and pricing up 10%+ in China due to supply caps. The shortage reflects advanced-node manufacturing constraints at Intel and reduced allocation to CPUs as TSMC prioritizes GPUs and NPUs for AI workloads, alongside pre-order overhang from memory price volatility and the computational demands of AI agents.

The Singapore Exchange (SGX) is expected to announce consolidation plans on Friday, February 13, 2026, following regulatory pressure and evolving market demands. The move aims to streamline operations and improve efficiency in preparation for expanded trading in the Asia-Pacific region.

The exchange has not released specific details on the structure of the consolidation, but preliminary reports indicate potential integration of its clearing and trading platforms. If finalized, the changes are expected to take effect in the first quarter of 2026, with potential impacts on listed companies' stock exchange fees and trading processes.